Page last updated: 2024-12-08

cucumopine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cucumopine: an opine from Agrobacterium vitis; RN given refers to cucumopine (4S-trans)-isomer; mikimopine is (4R-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441561
CHEBI ID3937
MeSH IDM0220236

Synonyms (15)

Synonym
1h-imidazo(4,5-c)pyridine-4-propanoic acid, 4,6-dicarboxy-4,5,6,7-tetrahydro-, (4s-trans)-
mikimopine
cucumopine
C08475
110342-24-0
(4s,6s)-4-(2-carboxyethyl)-1,5,6,7-tetrahydroimidazo[4,5-c]pyridine-4,6-dicarboxylic acid
AC1L9BBM ,
CTK0H8530 ,
3h-imidazo[4,5-c]pyridine-4,6-dicarboxylicacid, 4-(2-carboxyethyl)-4,5,6,7-tetrahydro-, (4s,6s)-
CHEBI:3937
DTXSID30149219
AKOS030241548
Q27106257
(4s,6s)-4-(2-carboxyethyl)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-4,6-dicarboxylic acid
(4s,6s)-4-(2-carboxyethyl)-1h,4h,5h,6h,7h-imidazo[4,5-c]pyridine-4,6-dicarboxylic acid

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (41.67)18.2507
2000's5 (41.67)29.6817
2010's1 (8.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]